Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | XPO1 | O14980 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9906892 | 0.82 | RAB9A (0.61) | RAB9ANPC1PTGS1GAADEGS1 | |
| SCHEMBL28211225 | 0.81 | RAB9A (0.53) | RAB9ANPC1PTGS1SMN1; SMN2GAA | |
| SCHEMBL20964573 | 0.80 | PRKAB2 (0.57) | RAB9ANPC1PTGS1SMN1; SMN2GAA | |
| SCHEMBL3620154 | 0.80 | RAB9A (0.68) | RAB9ANPC1PTGS1SMN1; SMN2GAA | |
| SCHEMBL3928750 | 0.79 | RAB9A (0.58) | RAB9ANPC1PTGS1SMN1; SMN2GAA | |
| SCHEMBL1464623 | 0.79 | GAA (0.49) | RAB9ANPC1PTGS1GAADEGS1 | |
| SCHEMBL19699480 | 0.79 | FFAR2 (0.62) | RAB9ANPC1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL5036428 | 0.79 | PTGS1 (0.66) | RAB9ANPC1PTGS1GAADEGS1 | |
| SCHEMBL2255178 | 0.79 | RAB9A (0.51) | RAB9ANPC1PTGS1GAADEGS1 | |
| SCHEMBL27350716 | 0.78 | RAB9A (0.57) | RAB9ANPC1PTGS1SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | CRBN, CDR2, CRKL | RAB9A 3648/4885NPC1 4014/4885PTGS1 3690/4885 |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | RAB9A 2299/4885NPC1 1904/4885PTGS1 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.